Tag: #fop

Articles related to fop

health

Garetosmab (Pasatru) sharply reduces new bone lesions in adults with FOP, phase 3 Lancet trial shows; FDA approved Aug. 19, 2026

Phase 3 Lancet trial shows garetosmab cuts new heterotopic bone lesions by ~90% in adults with FOP; FDA approved Pasatru Aug. 19, 2026.

#fop, #garetosmab, #raredisease, #fda